key: cord-0258946-0925f604 authors: Broadbent, Lindsay; Bamford, Connor G.G.; Campos, Guillermo Lopez; Manzoor, Sheerien; Courtney, David; Ali, Ahlam; Touzelet, Olivier; McCaughey, Conall; Mills, Ken; Power, Ultan F. title: An Endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells date: 2021-08-18 journal: bioRxiv DOI: 10.1101/2021.08.17.456707 sha: 9737dd07d6b360423dafe2dd351f22aa0c4d19e5 doc_id: 258946 cord_uid: 0925f604 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the coronavirus disease-19 (COVID-19) pandemic, was identified in late 2019 and went on to cause over 3.3 million deaths in 15 months. To date, targeted antiviral interventions against COVID-19 are limited. The spectrum of SARS-CoV-2 infection ranges from asymptomatic to fatal disease. However, the reasons for varying outcomes to SARS-CoV-2 infection are yet to be elucidated. Here we show that an endogenously activated interferon lambda (IFNλ) pathway leads to resistance against SARS-CoV-2 infection. Using a well-differentiated primary nasal epithelial cell (WD-PNEC) model from multiple adult donors, we discovered that susceptibility to SARS-CoV-2 infection, but not respiratory syncytial virus (RSV) infection, varied. One of four donors was resistant to SARS-CoV-2 infection. High baseline IFNλ expression levels and associated interferon stimulated genes correlated with resistance to SARS-CoV-2 infection. Inhibition of the JAK/STAT pathway in WD-PNECs with high endogenous IFNλ secretion resulted in higher SARS-CoV-2 titres. Conversely, prophylactic IFNλ treatment of WD-PNECs susceptible to infection resulted in reduced viral titres. An endogenously activated IFNλ response, possibly due to genetic differences, may be one explanation for the differences in susceptibility to SARS-CoV-2 infection in humans. Importantly, our work supports the continued exploration of IFNλ as a potential pharmaceutical against SARS-CoV-2 infection. In late 2019 a novel coronavirus, severe acute respiratory syndrome coronavirus 2 45 (SARS-CoV-2), emerged in Hubei province in China 1,2 . This virus is the causative agent 46 of the coronavirus disease-19 (COVID-19) pandemic, which has resulted in over 4.2 47 million deaths worldwide (as of August 2021). SARS-CoV-2 can infect people of any age. 48 However, severe disease disproportionately affects older individuals or those with 49 underlying health conditions. Clinical manifestations of SARS-CoV-2 infection range from 50 asymptomatic or very mild symptoms to severe illness requiring hospitalization and death. 51 COVID-19 disease is primarily a lung disease, typically manifesting itself as acute 52 respiratory distress syndrome in severe cases, although extra-pulmonary complications, 53 including cardiac, vascular, kidney and neurological pathologies, are also evident 3 . 54 Furthermore, coagulopathies are commonly reported in COVID-19 disease patients. 55 Reasons for the extreme variation in disease outcomes remain to be elucidated. in the cellular transcriptome and the activation of interferon-stimulated genes (ISGs), 74 many of which have antiviral activities 8 . Patients with COVID-19 have low serum levels of 75 type I and III IFNs but high levels of pro-inflammatory chemokines and cytokines 9 . 76 However, it has been observed that higher serum IFN correlates positively with viral load 77 and disease severity 10 . It is hypothesized that dysregulated, reduced or delayed IFN 78 responses, in combination with high cytokine levels, results in more severe COVID-19 79 disease 11 . 80 Unlike type I IFN receptors, the IFNλ receptor, IFNLR1, is not ubiquitously expressed and 81 is present predominantly on epithelial cells at barrier tissues like the lungs and 82 gastrointestinal tract 12 . As such, type III IFNs are considered to produce a more localised 83 response to infection in comparison to the systemic inflammatory response often induced 84 by type I IFN 13 . SARS-CoV-2 has been shown to induce an IFN response in epithelial 85 cells, the timing of which is delayed with regard to peak viral replication. Pre-treatment of 86 cells with IFNs is effective at blocking SARS-CoV-2 infection, and several directly anti-87 SARS-CoV-2 ISGs have been discovered, such as Ly6, OAS1 and IFITMs 14-16 . 88 As the primary target of SARS-CoV-2 infection is the airway epithelium, models that 89 authentically recreate the physiology and morphology of human airway epithelium in vivo 90 will undoubtedly be important tools to address fundamental questions about 91 human/SARS-CoV-2 interactions and subsequent innate immune responses. Therefore, 92 in this study we report differential susceptibility to SARS-CoV-2 infection in well-93 differentiated primary nasal epithelial cell (WD-PNEC) cultures derived from adult donors. 94 We obtained nasal brushings from 4 healthy donors with no previous history of SARS-95 CoV-2 infection. Interestingly, we found dramatically different susceptibility to SARS-CoV-96 2 infection, with 1 of the 4 donors being resistant. The resistance was likely mediated by 97 high endogenous IFNL expression and associated ISG responses. These data may 98 provide an explanation as to why some individuals experience asymptomatic infection 99 following exposure to SARS-CoV-2. 100 Surprisingly, however, we provide robust evidence of differential susceptibility of airway 198 epithelium to SARS-CoV-2 infection, with airway epithelium from some individuals being 199 highly susceptible and others resistant. Our data suggest that resistance is likely 200 mediated in part by type III IFNs. Thus, we provide a potential explanation as to why some 201 individuals may be able to control initial SARS-CoV-2 infection. 202 The household secondary attack rate for SARS-CoV-2 is estimated to be 16.6%, higher 203 than that of SARS-CoV (7.5%) and MERS (4.7%) 21 The SARS-CoV-2 clinical isolate BT20.1 was isolated from a patient admitted to Royal 274 Victoria Hospital, Belfast in June 2020. Characterisation of this strain has previously been 275 sequence reads were quality checked with FastQC and pre-processed for the sequence 318 cleaning and adapter removal using cutadapt 2.1 and Trim Galore! To remove adapter 319 contamination. (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). 320 These pre-processed fastq files were then aligned to the human genome GRCh38v33 321 using STAR aligner version 2.7.3a 42 using default parameters and subsequently genes 322 were quantified using htseq version 0.11.3 43 . 323 Quantified genes (raw counts) were processed using edgeR 44 for normalisation purposes 324 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 A pneumonia outbreak associated with a new coronavirus of 354 probable bat origin A Novel Coronavirus from Patients with Pneumonia in China Full spectrum of COVID-19 severity 358 still being depicted Tissue distribution of ACE2 protein, the functional receptor for 360 SARS coronavirus. A first step in understanding SARS pathogenesis Cell entry mechanisms of SARS-CoV-2 An inflammatory cytokine signature predicts COVID-19 365 severity and survival Cytokine elevation in severe and critical COVID-19: a rapid 367 systematic review, meta-analysis, and comparison with other inflammatory 368 syndromes Fundamental properties of the mammalian innate immune 370 system revealed by multispecies comparison of type I interferon responses Imbalanced Host Response to SARS-CoV-2 Drives 373 Development of COVID-19 Longitudinal analyses reveal immunological misfiring in severe 375 COVID-19 Untuned antiviral immunity in COVID-19 revealed by temporal 377 type I/III interferon patterns and flu comparison IFN-lambda (IFN-lambda) is 379 expressed in a tissue-dependent fashion and primarily acts on epithelial cells in 380 vivo Kinetic differences in the induction of interferon stimulated genes by 382 interferon-α and interleukin 28B are altered by infection with hepatitis C virus A Neanderthal OAS1 isoform protects individuals of European 385 ancestry against COVID-19 susceptibility and severity LY6E impairs coronavirus fusion and confers immune control 388 of viral disease The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates 390 Viral Sensitivity to Type I Interferon and IFITM2 Type I and Type III Interferons Restrict SARS-CoV-2 392 Infection of Human Airway Epithelial Cultures In vitro modeling of respiratory syncytial virus infection of 394 pediatric bronchial epithelium, the primary target of infection in vivo